CompletedPhase 3NCT00003350
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Studying Kaposi sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jamie Von RoennEastern Cooperative Oncology Group
- Intervention
- paclitaxel(drug)
- Enrollment
- 240 target
- Eligibility
- 18 years · All sexes
- Timeline
- 1999
Study locations (1)
- Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003350 on ClinicalTrials.govOther trials for Kaposi sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06445166Propranolol for the Treatment of Kaposi Sarcoma in AdultsWashington University School of Medicine
- RECRUITINGNCT06751355Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility TrialWashington University School of Medicine
- RECRUITINGNCT06375122Natural History Study of Kaposi SarcomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04305691Trial of Ixazomib for Kaposi SarcomaAIDS Malignancy Consortium
- ACTIVE NOT RECRUITINGPHASE1NCT05646082Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi SarcomaImperial College London
- ACTIVE NOT RECRUITINGPHASE2NCT04577755Pomalidomide Treatment in Patients With Kaposi SarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT04742387Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal AnalysisNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT03993106A Study of sEphB4-HSA in Kaposi SarcomaVasgene Therapeutics, Inc